成都市 · 医药生物
科伦药业 002422
Sichuan Kelun Pharmaceutical Co.,Ltd.
Since 2021, 科伦药业 has published 18 hedging-related filings on cninfo, the most recent dated 2026-04-03. The full timeline is below; every entry links to the source document.
Instruments disclosed
Unspecified 6 · FX 12
First appearance in this dataset: 2021-02-09
Core product types
专科用制剂、五官科用制剂、原料药、抗肿瘤制剂、植物类中药制剂、消化系统用制剂、神经系统用制剂、血液系统用制剂、非抗生素类抗感染制剂
Position in the chain
Upstream：中药提取物、中药饮片、制药机械、医药中间体 ｜ Downstream：兽药、呼吸系统用制剂、循环系统用制剂、抗生素类抗感染制剂
Hedging filing timeline
2026
- Unspecified Feasibility report
- Unspecified Programme announcement
2025
- Unspecified Policy document
- Unspecified Policy document
- Unspecified Programme announcement
- Unspecified Feasibility report
2024
- FX Programme announcement
- FX Feasibility report
- FX Feasibility report
-
长江证券承销保荐有限公司关于四川科伦药业股份有限公司预计2024年度日常关联交易暨开展外汇套期保值业务的核查意见
FX Programme announcement - FX Programme announcement
2023
- FX Programme announcement
- FX Feasibility report
-
长江证券承销保荐有限公司关于四川科伦药业股份有限公司预计2023年度日常关联交易、利用自有资金购买理财产品暨开展外汇套期保值业务的核查意见
FX Programme announcement
2022
- FX Feasibility report
- FX Programme announcement
2021
- FX Feasibility report
- FX Programme announcement First
Every row above is a filing title and date published by the company itself. This site adds no interpretation, passes no judgement on the arrangements, and offers no investment advice. The filings on cninfo are authoritative.